Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 4Active not recruiting 3Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

Specimen Handling 79Bevacizumab 66Drug Therapy 65Cisplatin 64Carboplatin 63Magnetic Resonance Spectroscopy 61Radiotherapy 57Cyclophosphamide 55Gemcitabine 54pembrolizumab 53Oxaliplatin 50Capecitabine 50toripalimab 42Paclitaxel 41tislelizumab 40Standard of Care 40Biopsy 37fludarabine 36Fluorouracil 35venetoclax 33Injections 33Blood Specimen Collection 31Immune Checkpoint Inhibitors 30anlotinib 29Nivolumab 29Surgical Procedures, Operative 28Irinotecan 27Docetaxel 27Dexamethasone 27Leucovorin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Medrol Veriderm × 1 year × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡